Rosiglitazone promotes AQP2 plasma membrane expression in renal cells via a ca-dependent/cAMP-independent mechanism

Cellular Physiology and Biochemistry

Volumn 35, Issue 3, 2015, Pages 1070-1085

  Procino, Giuseppe ^a   Gerbino, Andrea ^a   Milano, Serena ^a   Nicoletti, Maria Celeste ^a   Mastrofrancesco, Lisa ^a   Carmosino, Monica ^a   Svelto, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Aquaporin 2; Calcium signaling; Edema; Rosiglitazone; Thiazolidinediones; Transient receptor potential; Vasopressin

Indexed keywords

AQUAPORIN 2; CALCIUM ION; CYCLIC AMP; ROSIGLITAZONE; RUTHENIUM RED; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AQP2 PROTEIN, HUMAN; CALCIUM CHANNEL; TRPV6 PROTEIN, HUMAN; VANILLOID RECEPTOR; VASOPRESSIN DERIVATIVE;

ARTICLE; CELL CULTURE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; KIDNEY CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; WATER PERMEABILITY; BIOSYNTHESIS; CALCIUM SIGNALING; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; EDEMA; ENDOCYTOSIS; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; HEART FAILURE; KIDNEY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

AQUAPORIN 2; CALCIUM CHANNELS; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE; CYCLIC AMP; EDEMA; ENDOCYTOSIS; EPITHELIAL CELLS; GENE EXPRESSION; HEART FAILURE; HUMANS; KIDNEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRPV CATION CHANNELS; VASOPRESSINS;

EID: 84923088100     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373933     Document Type: Article

References (77)

1. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-192.
2. Fuchtenbusch M, Standl E, Schatz H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:151-163.
3. Cariou B, Charbonnel B, Staels B: Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-215.
4. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK: Recent developments and biological activities of thiazolidinone derivatives: a review. Bioorg Med Chem 2012;20:3378-3395.
5. Kung J, Henry RR: Thiazolidinedione safety. Expert Opin Drug Saf 2012;11:565-579.
6. Beltowski J, Rachanczyk J, Wlodarczyk M: Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res 2013;2013:628628.
7. Patel C, Wyne KL, McGuire DK: Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2005;2:61-66.
8. Yang T: Kidney-specific gene targeting: insight into thiazolidinedione-induced fluid retention. Nephrology (Carlton) 2006;11:201-206.
9. Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, Zhang Y: New Insights into the PPAR gamma Agonists for the Treatment of Diabetic Nephropathy. PPAR Res 2014;2014:818530.
10. Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997;273:F1013-1022.
11. Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, Brown J: PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J 2003;17:1966-1968.
12. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC, 3rd, Schnermann JB, Briggs JP: Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-973.
13. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA: Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004;308:426-433.
14. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005;102:9406-9411.
15. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J: Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 2009;20:721-729.
16. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205-244.
17. Tamma G, Procino G, Svelto M, Valenti G: Cell culture models and animal models for studying the patho-physiological role of renal aquaporins. Cellular and molecular life sciences: CMLS 2012;69:1931-1946.
18. Valenti G, Procino G, Tamma G, Carmosino M, Svelto M: Minireview: aquaporin 2 trafficking. Endocrinology 2005;146:5063-5070.
19. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA: Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Nat Acad Scie USA 1995;92:1013-1017.
20. Bouley R, Hasler U, Lu HA, Nunes P, Brown D: Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Seminars Nephrol 2008;28:266-278.
21. Wesche D, Deen PM, Knoers NV: Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012;27:2183-2204.
22. Moeller HB, Rittig S, Fenton RA: Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013;34:278-301.
23. Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM: Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res 2008;57:383-392.
24. Procino G, Barbieri C, Tamma G, De Benedictis L, Pessin JE, Svelto M, Valenti G: AQP2 exocytosis in the renal collecting duct-involvement of SNARE isoforms and the regulatory role of Munc18b. J Cell Sci 2008;121:2097-2106.
25. Tamma G, Procino G, Strafino A, Bononi E, Meyer G, Paulmichl M, Formoso V, Svelto M, Valenti G: Hypotonicity induces aquaporin-2 internalization and cytosol-to-membrane translocation of ICln in renal cells. Endocrinology 2007;148:1118-1130.
26. Christensen BM, Zelenina M, Aperia A, Nielsen S: Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist treatment. Am J Physiol Renal Physiol 2000;278:F29-42.
27. Stoos BA, Naray-Fejes-Toth A, Carretero OA, Ito S, Fejes-Toth G: Characterization of a mouse cortical collecting duct cell line. Kidney Int 1991;39:1168-1175.
28. Iolascon A, Aglio V, Tamma G, D'Apolito M, Addabbo F, Procino G, Simonetti MC, Montini G, Gesualdo L, Debler EW, Svelto M, Valenti G: Characterization of two novel missense mutations in the AQP2 gene causing nephrogenic diabetes insipidus. Nephron Physiol 2007;105:33-41.
29. Post SR, Rump LC, Zambon A, Hughes RJ, Buda MD, Jacobson JP, Kao CC, Insel PA: ATP activates cAMP production via multiple purinergic receptors in MDCK-D1 epithelial cells. Blockade of an autocrine/paracrine pathway to define receptor preference of an agonist. J Biol Chem 1998;273:23093-23097.
30. Deen PM, Rijss JP, Mulders SM, Errington RJ, van Baal J, van Os CH: Aquaporin-2 transfection of Madin-Darby canine kidney cells reconstitutes vasopressin-regulated transcellular osmotic water transport. J Am Soc Nephrol 1997;8:1493-1501.
31. van der Krogt GN, Ogink J, Ponsioen B, Jalink K: A comparison of donor-acceptor pairs for genetically encoded FRET sensors: application to the Epac cAMP sensor as an example. PLoS One 2008;3:e1916.
32. Caddy J, Singh N, Atkin L, Ahluwalia M, Roberts A, Lang D, Thomas AW, Webb R: Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells. Biochem Biophys Res Commun 2008;366:149-155.
33. Woudenberg-Vrenken TE, Bindels RJ, Hoenderop JG: The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 2009;5:441-449.
34. Garcia RL, Schilling WP: Differential expression of mammalian TRP homologues across tissues and cell lines. Biochem Biophys Res Commun 1997;239:279-283.
35. Groschner K, Hingel S, Lintschinger B, Balzer M, Romanin C, Zhu X, Schreibmayer W: Trp proteins form store-operated cation channels in human vascular endothelial cells. FEBS Lett 1998;437:101-106.
36. Wu X, Babnigg G, Zagranichnaya T, Villereal ML: The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. J Biol Chem 2002;277:13597-13608.
37. Bugaj V, Alexeenko V, Zubov A, Glushankova L, Nikolaev A, Wang Z, Kaznacheyeva E, Bezprozvanny I, Mozhayeva GN: Functional properties of endogenous receptor-and store-operated calcium influx channels in HEK293 cells. J Biol Chem 2005;280:16790-16797.
38. Wu L, Gao X, Brown RC, Heller S, O'Neil RG: Dual role of the TRPV4 channel as a sensor of flow and osmolality in renal epithelial cells. Am J Physiol Renal Physiol 2007;293:F1699-1713.
39. Berrout J, Jin M, Mamenko M, Zaika O, Pochynyuk O, O'Neil RG: Function of transient receptor potential cation channel subfamily V member 4 (TRPV4) as a mechanical transducer in flow-sensitive segments of renal collecting duct system. J Biol Chem 2012;287:8782-8791.
40. Vriens J, Appendino G, Nilius B: Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009;75:1262-1279.
41. Bolanz KA, Hediger MA, Landowski CP: The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 2008;7:271-279.
42. Bolanz KA, Kovacs GG, Landowski CP, Hediger MA: Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells. Mol Cancer Res 2009;7:2000-2010.
43. Wang F, Aleksunes LM, Reagan LA, Vergara CM: Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technol Ther 2002;4:505-514.
44. Mudaliar S, Chang AR, Henry RR: Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9:406-416.
45. Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK: GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 2005;312:718-725.
46. Knepper MA, Kim GH, Fernandez-Llama P, Ecelbarger CA: Regulation of thick ascending limb transport by vasopressin. J Am Soc Nephrol 1999;10:628-634.
47. Kim GH, Ecelbarger CA, Mitchell C, Packer RK, Wade JB, Knepper MA: Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol 1999;276:F96-F103.
48. Hozawa S, Holtzman EJ, Ausiello DA: cAMP motifs regulating transcription in the aquaporin 2 gene. Am J Physiol 1996;270:C1695-1702.
49. Matsumura Y, Uchida S, Rai T, Sasaki S, Marumo F: Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 1997;8:861-867.
50. Rieg T, Tang T, Uchida S, Hammond HK, Fenton RA, Vallon V: Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin-induced phosphorylation of NKCC2 and NCC. Am J Pathol 2013;182:96-106.
51. Fushimi K, Sasaki S, Marumo F: Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 1997;272:14800-14804.
52. Kortenoeven ML, Fenton RA: Renal aquaporins and water balance disorders. Biochim Biophys Acta 2013;10.1016/j.bbagen.2013.12.002
53. Nishimoto G, Zelenina M, Li D, Yasui M, Aperia A, Nielsen S, Nairn AC: Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat renal tissue. Am J Physiol 1999;276:F254-259.
54. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D: Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol 2005;288:F1103-1112.
55. Li W, Zhang Y, Bouley R, Chen Y, Matsuzaki T, Nunes P, Hasler U, Brown D, Lu HA: Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Renal Physiol 2011;301:F309-318.
56. Olesen ET, Rutzler MR, Moeller HB, Praetorius HA, Fenton RA: Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Nat Acad Sci USA 2011;108:12949-12954.
57. Procino G, Barbieri C, Carmosino M, Rizzo F, Valenti G, Svelto M: Lovastatin-induced cholesterol depletion affects both apical sorting and endocytosis of aquaporin-2 in renal cells. Am J Physiol Renal Physiol 2010;298:F266-278.
58. Procino G, Barbieri C, Carmosino M, Tamma G, Milano S, De Benedictis L, Mola MG, Lazo-Fernandez Y, Valenti G, Svelto M: Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch 2011;462:753-766.
59. Procino G, Milano S, Carmosino M, Barbieri C, Nicoletti MC, J HL, Wess J, Svelto M: Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice. Kidney Int 2014;10.1038/ki.2014.10
60. Burgoyne RD, Barclay JW, Ciufo LF, Graham ME, Handley MT, Morgan A: The functions of Munc18-1 in regulated exocytosis. Ann N Y Acad Sci 2009;1152:76-86.
61. Jolly C, Sattentau QJ: Regulated secretion from CD4+ T cells. Trends Immunol 2007;28:474-481.
62. Lacy P, Stow JL: Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 2011;118:9-18.
63. Procino G, Mastrofrancesco L, Tamma G, Lasorsa DR, Ranieri M, Stringini G, Emma F, Svelto M, Valenti G: Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One 2012;7:e33145.
64. Lee TI, Chen YC, Kao YH, Hsiao FC, Lin YK, Chen YJ: Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration. Int J Cardiol 2013;165:299-307.
65. Shah RD, Gonzales F, Golez E, Augustin D, Caudillo S, Abbott A, Morello J, McDonough PM, Paolini PJ, Shubeita HE: The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha-and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Cell Physiol Biochem 2005;15:41-50.
66. Singh N, Webb R, Adams R, Evans SA, Al-Mosawi A, Evans M, Roberts AW, Thomas AW: The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. Biochem Biophys Res Commun 2005;333:455-462.
67. Majeed Y, Bahnasi Y, Seymour VA, Wilson LA, Milligan CJ, Agarwal AK, Sukumar P, Naylor J, Beech DJ: Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol 2011;79:1023-1030.
68. Galizia L, Pizzoni A, Fernandez J, Rivarola V, Capurro C, Ford P: Functional interaction between AQP2 and TRPV4 in renal cells. J Cell Biochem 2012;113:580-589.
69. Pochynyuk O, Zaika O, O'Neil RG, Mamenko M: Novel insights into TRPV4 function in the kidney. Pflugers Arch 2013;465:177-186.
70. Praetorius HA, Spring KR: A physiological view of the primary cilium. Annu Rev Physiol 2005;67:515-529.
71. Du J, Wong WY, Sun L, Huang Y, Yao X: Protein kinase G inhibits flow-induced Ca2+ entry into collecting duct cells. J Am Soc Nephrol 2012;23:1172-1180.
72. Hoenderop JG, Bindels RJ: Calciotropic and magnesiotropic TRP channels. Physiology (Bethesda) 2008;23:32-40.
73. Nijenhuis T, Hoenderop JG, van der Kemp AW, Bindels RJ: Localization and regulation of the epithelial Ca2+ channel TRPV6 in the kidney. J Am Soc Nephrol 2003;14:2731-2740.
74. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Kim SY, Hahn SJ: Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedebergs Arch Pharmacol 2007;374:305-309.
75. Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG: Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia 2008;51:675-685.
76. Jeong I, Choi BH, Hahn SJ: Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation. Br J Pharmacol 2011;163:510-520.
77. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O: Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 2009;109:1800-1811.